Does untreated celiac disease associated with type 1 diabetes mellitus worsen microvascular outcomes? Previous studies have concluded that a gluten-free diet offers no major benefit for glycemic control, whereas Leeds and colleagues provide preliminary data to the contrary. The question awaits a long-term prospective study or a clinical trial.
Data are lacking concerning the effect of celiac disease on diabetes-related complications among adults with type 1 diabetes mellitus (T1DM). A recent study by Leeds et al. 1 attempted to partially fill this gap and add a provocative twist to the picture by suggesting that adults with undetected celiac disease and T1DM have worse glycemic control and an increased prevalence of retinopathy and nephropathy.
Celiac disease prevalence and associated mortality have increased dramatically in the USA during the past 50 years.
2 Evidence is growing that diagnosis is delayed by years or even decades in a large proportion of patients with this disease, despite the availability of a highly sensitive and specific test, which involves the detection of transglutaminase autoantibodies.
3 Untreated celiac disease is associated with increased morbidity and mortality. 4 By contrast, early initiation of a gluten-free diet prolongs life and saves health-care expenditures. 5 Celiac disease affects at least 10% of patients with T1DM at some point in their lives. 6 The increased prevalence of celiac disease in patients with T1DM is due to an overlap in the genetic susceptibility to both diseases conferred by the human leukocyte antigen (HLA) haplotype HLA-DR3/DQ2. This haplotype is pre sent in over 90% of patients with celiac dis ease and 55% of those with T1DM, compared with only 20-25% of the general population of European ancestry. The second HLA class II allele important for celiac dis ease (DQ8) also confers risk of T1DM. Several shared non-HLA susceptibility genes (which have a much smaller effect compared with HLA loci for both celiac dis ease and T1DM) have also been confirmed. Hypotheses proposing common environmental roots of these two auto immune diseases have not been support ed by recent investigations.
7
Guidelines from professional societies recom mend screening patients with T1DM for celiac disease using transglutaminase auto antibodies. Children with T1DM who have symptomatic celiac disease have been shown to benefit from a gluten-free diet; 8 in asympto matic cases, the benefit appears to be limited to growth and bone mineralization.
9 Additional reasons to screen patients with T1DM for celiac disease include anecdotal reports of an increased risk of hypo glycemia and higher HbA 1c levels in untreated children, 6 but these findings were unconfirmed in prospective follow-up studies.
9 On the other hand, a gluten-free diet often requires an increase in insulin dose and can lead to excessive weight gain.
Leeds et al. screened 1,000 consecutive patients with a clinical diagnosis of T1DM, who attended a secondary-care clinic, for IgA deficiency, transglutaminase autoantibodies and endomysial auto antibodies (a positive result for endomysial autoantibodies simply corresponds to hightiter transglutaminase autoantibodies). Of the 1,000 patients, 21 had known celiac disease and an additional 82 had either IgA deficiency or elevated levels of endomysial or transglutaminase autoantibodies. Duodenal biopsy was performed in 78 of these 82 patients, which confirmed celiac disease (Marsh grade 3 mucosal atrophy) in 12 individuals. Characteristics of the 12 patients with newly diagnosed celiac disease and 24 control individuals with T1DM who screened negative for celiac disease were compared at baseline, and also at 1 year when the group with celiac disease had received a gluten-free diet for 12 months.
Despite a very small sample size, the authors reported that, at baseline, the patients with newly diagnosed celiac dis ease had higher HbA 1c levels, lower total and HDL cholesterol levels and a higher prevalence of advanced diabetic nephro pathy and retino pathy compared with patients without celiac disease. Advanced nephro pathy and retino pathy were not clearly defined. HbA 1c was apparently measured using two differ ent methods during the study period, and the control group, although reported as 'matched' for duration of T1DM, had a 6-year longer mean dura tion than the celiac dis ease group. No compari son of diabetesrelated outcomes was provided between the 12 newly diagnosed cases of celiac disease and the 21 patients with known celiac disease. Such a comparison could have shed light on why the newly diagnosed group had not pre viously been diagnosed, despite the fact that many had gastrointestinal symptoms or anemia. Limited contact with diabetes care providers or low socio economical status could have been unmeasured confounders associated with both delayed diagnosis of celiac disease and high HbA 1c levels and microvascular complications.
The inspection of results of the reported 1-year follow-up of cases and controls makes us wonder about the quality of the data. After being newly diagnosed with celiac disease, a gluten-free diet was recom mended for the 12 patients and nine complied, as judged by the decreased levels of trans glutaminase or endomysial auto antibodies that were found at follow-up after 1 year. The control patients, who had a normal diet, were also followed for 1 year. Most parameters did not change during the follow-up. However, some of the reported changes appear il logical and so should have been explained in the discussion. For example, the estimated glomerular filtration rate worsened during the year among the 12 patients with celiac disease, from 96 ml/min/1.73 m 2 to 84 ml/min/1.73 m 2 , but the number of indivi duals classified as having 'nephropathy stage >3' decreased from five to two. Curiously, although weight did not change in the patients with celiac dis ease, the control individuals gained an average of 5.2 kg and their HbA 1c level worsened from 7.5% to 8.5%, triglycerides improved from 0.75 mmol/l to 0.65 mmol/l, but insulin dose did not change. The HbA 1c levels in con trol individuals at 1 year (8.5%) were slightly higher than those in the patients with celiac disease at baseline (8.2%), which negates the main conclusion of this study that adults with undetected celiac disease and T1DM have worse glycemic control than patients with T1DM without celiac disease.
Is it time to draw the curtain on the main hypo thesis of this study? Certainly not, but the article by Leeds et al suffers from too many limitations to draw any firm 
PEDIATRICS
Measuring pediatric BMD-the bar raised but the glass half full
Craig B. Langman
Extensive reference data sets of pediatric bone density measurements are now available, together with equations to translate BMD into relevant Z-scores and correct for abnormal stature. So now is the right time to ask: are you thinking about bone density in children correctly?
Langman, C. B. Nat. Rev. Endocrinol. 8, 8-9 (2012) When we practice medicine and obtain a serum sodium level in a given patient, we are certain to a very high degree that the measurement is both accurate and highly reproducible. Furthermore, we are just as confident in the normal value we are expecting for it. The same cannot be said about bone density measurement in children. Zemel and colleagues 1 have now provided the most robust reference values for pediatric bone density to date.
The longitudinal study involved >2,000 children and young adults aged 5-20 years from five clinical centers in the USA whose bone mineral content (BMC) and areal BMD were assessed annually for up to 7 years. The assessments provided ~10,000 data points for BMC and areal BMD of the total body less head, the lumbar spine, the total hip and the femur using results from dual energy x-ray absorptio metry (DXA) scans. By use of sophisticated model ing software and by dividing the data into sets for black and nonblack children they provide us with both extensive normative data and also robust equations with which to statistically recalculate DXA-based bone density Z-scores in children with altered growth who undergo the test.
Importantly, complete overlap and no differences for total hip and femoral neck BMD were found when the data from the current study were compared with those from a recent NHANES study of the same chil dren, in which the researchers employed slightly different methodologies to create the reference curve. This finding underscores the accuracy of the report by Zemel and co-workers.
So what is the problem in pediatric bone density measurement? Unlike the serum sodium value that we measure across multiple platforms but in which the norma tive values are unchanged, BMC and areal BMD values are dependent on the particular type of DXA machine used and are not absolute.
Gafni and Baron have reported that up to 75% of children are erroneously diagnosed as having a low BMD (Z-score ≤-2) after a DXA scan. The reasons included methodological issues of inattention to the cor rect data set, the use of a T-score (the mean BMD at age 30 years, which of course cannot be applied to developing children) or interpreting the results without relation to stature, a known confounder of the measure ment.
2
The importance of the reference data set was stressed over a decade ago, when assignment of osteopenia in children varied threefold depending on which set was used.
3
In regard to the last point, the current article by Zemel et al. lays to rest the confusing issue of reference data sets, or does it? In clinical practice, we often see patients whose bone density is measured at outside sites, using DXA machines produced by manufacturers different to the one refer enced in the current report, and with follow-up scans often performed using machines that differ from those used for baseline measurements. Moreover, the intricacies of pediatric bone density measurement, 4 including the use of specialized software, were given great attention in the report by Zemel et al. but are often not evident in communityacquired measure ment of bone density in children. Zemel and colleagues enrolled only chil dren born at term, and we remain unsure of the effects of very premature and premature birth on subsequent development of bone density in the early childhood years, although a healthy preterm gestation apparently has no long-term effect on adult BMD. ''
